

Carey E Gleason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/579332/publications.pdf>

Version: 2024-02-01

79
papers

2,002
citations

318942

23
h-index

286692

43
g-index

115
all docs

115
docs citations

115
times ranked

3382
citing authors

#	ARTICLE	IF	CITATIONS
1	Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing. <i>Alzheimer's and Dementia</i> , 2022, 18, 1969-1979.	0.4	8
2	The Wisconsin Alzheimer's Institute Dementia Diagnostic Clinic Network: A community of practice to improve dementia care. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2121-2133.	1.3	4
3	Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence. <i>Alzheimer's and Dementia</i> , 2022, 18, 1545-1564.	0.4	29
4	What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1167-1179.	1.2	7
5	Anticipated reactions to learning Alzheimer's disease biomarker results. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	3
6	Latent Factor Structure and Measurement Invariance of the NIH Toolbox Cognition Battery in an Alzheimer's Disease Research Sample. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 412-425.	1.2	13
7	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. <i>Neurology</i> , 2021, 96, e2500-e2512.	1.5	32
8	Relationships between well-being and cognitive function among Native American, Black, and White participants in the Wisconsin Alzheimer's Disease Research Center. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
9	Greater COVID-19 impact for underrepresented racial and ethnic minority groups: A survey study on the Wisconsin Alzheimer's Disease Research Center participants. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
10	Differential discordance of informant- and self-rated depression and apathy in Black, Hispanic, and White participants in the NACC dataset. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
11	Prevalence of modifiable risk factors for Alzheimer's disease and related dementias, and association with cognitive disability among transgender and gender non-binary adults in the U.S.: BRFSS 2019. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
12	Differential measurement of depression by racial group: Findings from an Alzheimer's Disease Center cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
13	Wisconsin healthcare utilization cost among American Indians/Alaskan Natives with and without ADRD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
14	Factors related to willingness to participate in AD biomarker studies that disclose personal results. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
15	Dietary carotenoids and cognitive function among US adults, NHANES 2011-2014. <i>Nutritional Neuroscience</i> , 2020, 23, 554-562.	1.5	40
16	Stressful Life Events and Racial Disparities in Cognition Among Middle-Aged and Older Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 671-682.	1.2	52
17	Validation of connected speech as a marker for cognitive change in late-middle aged African American adults at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e036861.	0.4	0
18	Preservation of white matter integrity on DTI 3 years after early menopausal hormone therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, e036886.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Effect of metabolic syndrome risk factors on processing speed in three racial groups. <i>Alzheimer's and Dementia</i> , 2020, 16, e039570.	0.4	0
20	Perspectives on dementia and family caregiving among the Oneida Nation of Wisconsin. <i>Alzheimer's and Dementia</i> , 2020, 16, e040652.	0.4	0
21	Prevalence of subjective cognitive decline higher among transgender and gender nonbinary adults in the U.S., 2016–2018. <i>Alzheimer's and Dementia</i> , 2020, 16, e044298.	0.4	1
22	The formation of the advisory group on risk evaluation education for dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e045562.	0.4	2
23	Association of Cardiovascular Risk Factors with Cerebral Perfusion in Whites and African Americans. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 649-660.	1.2	11
24	Learning from Transmasculine Experiences with Health Care: Tangible Inlets for Reducing Health Disparities Through Patient–Provider Relationships. <i>Transgender Health</i> , 2020, 5, 18-32.	1.2	12
25	Research Participant Interest in Alzheimer's Disease Biomarker Disclosure. <i>Innovation in Aging</i> , 2020, 4, 880-880.	0.0	0
26	Perspectives on Dementia Service Use and Family Caregiving Among the Oneida Nation of Wisconsin. <i>Innovation in Aging</i> , 2020, 4, 710-710.	0.0	0
27	Factors Associated with Lumbar Puncture Participation in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1559-1567.	1.2	19
28	Association of Cardiovascular and Alzheimer's Disease Risk Factors with Intracranial Arterial Blood Flow in Whites and African Americans. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 919-929.	1.2	14
29	Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center. <i>Alzheimer's and Dementia</i> , 2019, 15, 1533-1545.	0.4	64
30	P4637: EXAMINING THE ROLE OF CIGARETTE SMOKING AND CESSATION ON COMBINED RISK OF INCIDENT DEMENTIA, NURSING HOME PLACEMENT, AND DEATH IN COGNITIVELY HEALTHY AND MILD COGNITIVELY IMPAIRED ADULTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P1571.	0.4	0
31	O20701: SLEEP QUALITY AND BETA-AMYLOID DEPOSITION IN RECENTLY MENOPAUSAL WOMEN PARTICIPATING IN THE KRONOS EARLY ESTROGEN PREVENTION STUDY (KEEPS). <i>Alzheimer's and Dementia</i> , 2019, 15, P551.	0.4	1
32	Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 751-770.	1.8	161
33	The recency ratio is related to CSF amyloid beta 142 levels in MCIAD. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 415-419.	1.3	12
34	Longitudinal Standards for Mid-life Cognitive Performance: Identifying Abnormal Within-Person Changes in the Wisconsin Registry for Alzheimer's Prevention. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 1-14.	1.2	19
35	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.5	57
36	P3285: INCIDENT DEMENTIA IN NON-HISPANIC AFRICAN AMERICANS AND WHITES WITH MILD COGNITIVE IMPAIRMENT: CAN WE MAKE RACIAL COMPARISONS USING ALZHEIMER'S DISEASE CENTER DATA?. <i>Alzheimer's and Dementia</i> , 2018, 14, P1188.	0.4	0

#	ARTICLE	IF	CITATIONS
37	P1â€286: TRANSFORMATION OF CSF BIOMARKER VALUES BETWEEN MEASUREMENT BATCHES. Alzheimer's and Dementia, 2018, 14, P393.	0.4	3
38	P2â€480: LATENT FACTOR STRUCTURE AND MEASUREMENT INVARIANCE OF THE NIH TOOLBOX COGNITION BATTERY IN A SAMPLE FROM THE WISCONSIN ALZHEIMER'S DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2018, 14, P909.	0.4	0
39	P3â€271: LUMBAR PUNCTURE SIDE EFFECT RATES IN A RESEARCH SETTING. Alzheimer's and Dementia, 2018, 14, P1180.	0.4	3
40	Cognitive Changes with Reproductive Aging, Perimenopause, and Menopause. Obstetrics and Gynecology Clinics of North America, 2018, 45, 751-763.	0.7	37
41	Association of the Haptoglobin Gene Polymorphism With Cognitive Function and Decline in Elderly African American Adults With Type 2 Diabetes. JAMA Network Open, 2018, 1, e184458.	2.8	17
42	F2â€01â€03: AN UPDATE ON MENOPAUSAL HORMONE THERAPY TRIALS. Alzheimer's and Dementia, 2018, 14, P602.		0
43	Cognitive Variability Predicts Incident Alzheimerâ€™s Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker. Journal of Alzheimer's Disease, 2017, 61, 79-89.	1.2	30
44	[O1â€04â€03]: NEIGHBORHOOD SOCIOECONOMIC CONTEXTUAL DISADVANTAGE, BASELINE COGNITION AND ALZHEIMER'S DISEASE BIOMARKERS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP) STUDY. Alzheimer's and Dementia, 2017, 13, P195.	0.4	2
45	[P2â€471]: LONGITUDINAL NORMS FOR MIDâ€LIFE COGNITIVE PERFORMANCE: IDENTIFYING ABNORMAL WITHINâ€PERSON CHANGES IN WRAP. Alzheimer's and Dementia, 2017, 13, P820.	0.4	0
46	[P3â€021]: THE ROLE OF CARDIOVASCULAR HEALTH IN MODERATING THE EFFECTS OF POSTMENOPAUSAL HORMONE THERAPY ON NEUROIMAGING OUTCOMES. Alzheimer's and Dementia, 2017, 13, P937.	0.4	0
47	[P4â€301]: COMPARING COGNITIVE BATTERIES: UNIFORM DATA SET 2 (UDSâ€2) AND UNIFORM DATA SET 3 (UDSâ€3) IN NONâ€HISPANIC WHITE PARTICIPANTS AND THOSE FROM UNDERREPRESENTED GROUPS ENROLLED IN THE WISCONSIN ALZHEIMER'S DISEASE RESEARCH CENTER'S CLINICAL CORE. Alzheimer's and Dementia, 2017, 13, P1405.	0.4	0
48	[P4â€378]: A MIXED METHODS ANALYSIS OF SOCIAL COGNITIVE FACTORS INFLUENCING AFRICAN AMERICANSâ€™ INTENTION TO BE SCREENED FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1437.	0.4	0
49	[P1â€526]: THE WRAPâ€AROUND APPROACH: A NOVEL RETENTION STRATEGY IN THE AAâ€FAIM STUDY. Alzheimer's and Dementia, 2017, 13, P495.	0.4	0
50	[O1â€09â€04]: LIFETIME STRESSFUL EXPERIENCES, RACIAL DISPARITIES, AND COGNITIVE PERFORMANCE: FINDINGS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP) STUDY. Alzheimer's and Dementia, 2017, 13, P212.	0.4	5
51	[FTS5â€02â€09]: AFRICAN AMERICANS FIGHTING ALZHEIMER'S IN MIDLIFE. Alzheimer's and Dementia, 2017, 13, P1450.	0.4	0
52	[O5â€01â€05]: COHORT AND RACE DIFFERENCES IN FACTORS ASSOCIATED WITH ATTRITION IN LONGITUDINAL STUDIES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1454.	0.4	1
53	[P4â€286]: A COMPARISON OF METHODS TO MEASURE INTRAâ€INDIVIDUAL COGNITIVE VARIABILITY IN NONâ€HISPANIC WHITES AND AFRICAN AMERICANS IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP). Alzheimer's and Dementia, 2017, 13, P1394.	0.4	0
54	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	1.2	51

#	ARTICLE	IF	CITATIONS
55	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe Î4 Carriers. , 2016, 12, P375-P376.		0
56	P2â€³63: A Mixed Methods Analysis of Social Cognitive Factors Influencing Older African Americans' Intention to be Screened for Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P784.	0.4	0
57	P4â€³35: Postmortem Cerebrovascular Disease and White Matter Pallor are Associated with Lower Antemortem Cerebral Perfusion, Increased White Matter Hyperintensities, and Poor Learning. Alzheimer's and Dementia, 2016, 12, P1162.	0.4	0
58	Cerebrospinal Fluid Markers of Alzheimerâ€™s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 873-886.	1.2	101
59	Cognitive variabilityâ€™A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 47-55.	1.2	22
60	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
61	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	1.2	94
62	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain, 2016, 139, 2261-2274.	3.7	41
63	Common Sense Model Factors Affecting African Americans' Willingness to Consult a Healthcare Provider Regarding Symptoms of Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2016, 24, 537-546.	0.6	8
64	P4-274: Intra-individual cognitive variability: An alternative to invasive Alzheimer's disease biomarkers?. , 2015, 11, P890-P891.		0
65	P3-103: Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer's disease: Findings from the wisconsin adrc impact cohort. , 2015, 11, P659-P660.		0
66	IC-P-096: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy APOE4 carriers. , 2015, 11, P66-P67.		0
67	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE Îµ4 carriers. , 2015, 11, P427-P428.		0
68	Cognitive Effects of Soy Isoflavones in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 1009-1019.	1.2	74
69	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE É4 Carriers. Journal of Alzheimer's Disease, 2015, 46, 525-533.	1.2	65
70	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPSâ€™Cognitive and Affective Study. PLoS Medicine, 2015, 12, e1001833.	3.9	330
71	The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. NeuroImage, 2015, 105, 357-368.	2.1	38
72	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. JAMA Neurology, 2015, 72, 699.	4.5	75

#	ARTICLE	IF	CITATIONS
73	The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 331-341.	1.2	25
74	Effects of hormone therapy on cognition and mood. <i>Fertility and Sterility</i> , 2014, 101, 898-904.	0.5	62
75	Cerebrospinal fluid sphingolipids, β -amyloid, and tau in adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2486-2494.	1.5	57
76	Using predictors of hormone therapy use to model the healthy user bias. <i>Menopause</i> , 2012, 19, 524-533.	0.8	14
77	Increased Risk for Falling Associated with Subtle Cognitive Impairment: Secondary Analysis of a Randomized Clinical Trial. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 557-563.	0.7	96
78	A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. <i>Age and Ageing</i> , 2008, 38, 86-93.	0.7	82
79	Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations. <i>Annals of the New York Academy of Sciences</i> , 2005, 1052, 93-115.	1.8	51